Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens, such as Roche / Genentech’s Zelboraf + Cotellic ± Tecentriq, Novartis’ Tafinlar + Mekinist, and Pfizer’s Braftovi + Mektovi, are key treatment options for malignant melanoma patients harboring BRAF mutations, while immune checkpoint inhibitors, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), offer therapeutic options to patients regardless of mutation status. Intratumoral treatment options are limited to Amgen’s oncolytic viral therapy Imlygic, available only to patients with injectable lesions that cannot be resected. This content explores key factors driving surveyed medical oncologists’ prescribing decisions when treating malignant melanoma patients
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 102 U.S. medical oncologists in March 2022.
Key drugs covered: Keytruda, Opdivo ± Yervoy, Zelboraf, Cotellic, Tafinlar, Mekinist, Braftovi, Mektovi, Imlygic.